
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is a surgical robotics company with a positive outlook due to its innovative solutions and focus on advancing patient care. Though there may be some short-term challenges in reaching their projected procedure numbers, the company is well-positioned for long-term success with its strong product line and expanding presence in both the US and international markets. Additionally, the recent increase in PAE reimbursement highlights the potential for further growth in the future.
Bears say
PROCEPT BioRobotics is facing several headwinds that could hinder its ability to achieve sustainable growth in the future. These include (1) a slowdown in procedure growth due to increased adoption of a competing procedure with higher profit margins, (2) a restructured sales force under new leadership with uncertain effectiveness, (3) potential headwinds from an upcoming increase in competition in the market for BPH treatment, and (4) potential pricing pressure and challenges with gaining favorable reimbursement. While the company has achieved growth in recent sales, these challenges raise concerns about its future performance and make it difficult for the stock to break out of its current trading range. As such, the analyst has a negative outlook on PROCEPT BioRobotics stock and has lowered their price target to $30.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares